Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01062230|
Recruitment Status : Terminated (Slow accrual; PI left primary institution)
First Posted : February 4, 2010
Results First Posted : April 6, 2015
Last Update Posted : April 6, 2015
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression. The dose of bortezomib used in this trial of 0.7 mg/m2 is the lowest dose which has shown efficacy in the 3 largest monotherapy trials with bortezomib. 17% of patients in the APEX, 9% patients in CREST and 24% in SUMMIT trials were treated with 0.7 mg/m2 dosages. Bortezomib will be given on days 1, 8, 15, 22 over 42 days to reduce the incidence of possible drug related side effects.
The primary objective of this study is to:
- To evaluate the effect of Velcade at 0.7 mg/m2 dose on inducing osteoblast activation as measured by ALP and other bone markers in patients with relapsed/refractory myeloma.
The secondary objectives of this study are to:
- To evaluate the association between osteoblastic activation and myeloma response to Velcade.
- To identify predictive factors for Velcade-associated osteoblastic activation.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Bortezomib (Velcade)||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
Experimental: All patients
All participants enrolled.
Drug: Bortezomib (Velcade)
Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.
Patients will undergo three 21-day cycles.
Other Name: Velcade
- Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 [ Time Frame: Baseline and Day 1 ]All patients received 0.7 mg/m2 of bortezomib on days 1, 4, 8 and 11 of a 21 day cycle, for maximum of three cycles for an average of 18 months. Intact Parathyroid hormone was measured in patients with relapsed/refractory myeloma for osteoblast activation. Other bone markers were examined using similar methods.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062230
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84112|
|Principal Investigator:||Maurizio Zangari, MD||University of Arkansas|